Life
White House Pushes for 'Most-Favored Nation' Drug Pricing Legislation
The White House is increasing its efforts to secure drug pricing reforms in Congress, focusing on a 'most-favored nation' policy that could reshape pharmaceutical pricing structures.
Editorial Staff
1 min read
On March 17, 2026, the White House announced an intensified campaign aimed at Congress to pass legislation that would establish a 'most-favored nation' drug pricing policy.
This policy aims to ensure that the prices paid for drugs by the U.S. are not higher than those paid by other countries, potentially altering the pricing dynamics within the pharmaceutical industry.
In parallel, developments regarding GSK's new asthma drug are being monitored, as they may also be influenced by these legislative changes and the broader drug pricing landscape.